ArticleBritish journal of cancer2017
Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- How exclusion criteria can hinder eligibility for lung cancer studies among different racial and ethnic groups.PLOS digital health · 2026Article
- The effect of thyroid cancer on the survival of patients with digestive system tumors using SEER database.Scientific reports · 2024Article
- Indeterminate pulmonary nodules and prior malignancy: survival and recurrence after surgery in newly diagnosed stage I non-small cell lung cancer.Journal of thoracic disease · 2024Article
- Medical history of thyroid cancer does not impair prognosis in non-metastatic breast cancer patients: an analysis study based on SEER database and external cohort.Frontiers in oncology · 2024Article
- Prognostic impact of the presence or absence of prior cancer in patients with cancer using cure models: A population-based study.Cancer science · 2023Article
- Survival in non-small cell lung cancer patients with versus without prior cancer.Scientific reports · 2023Article
- Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?BMC cancer · 2023Article
- Prognosis of male lung cancer patients with urinary cancer: a study from a national population-based analysis.Scientific reports · 2023Article
- Effect of sponsor on enrollment criteria in non-small cell lung cancer clinical trials.Journal of cancer policy · 2022Article
- How inclusive are cell lines in preclinical engineered cancer models?Disease models & mechanisms · 2022Article
- Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials.Cancers · 2022Article
- Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation.World journal of clinical cases · 2022Article
- Lung Cancer Computational Biology and Resources.Cold Spring Harbor perspectives in medicine · 2022Review
- Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis.Frontiers in oncology · 2022Article
- The Impact of a History of Different Other Cancers on the Long-Term Outcomes of Patients with Intrahepatic Cholangiocarcinoma: A Population-Based Analysis.BioMed research international · 2022Article
- The effect of prior cancer on non-small cell lung cancer trial eligibility.Cancer medicine · 2021Article
- Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- Article
- Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria.BMC cancer · 2021Article
- The impact of a prior malignancy on outcomes in gastric cancer patients.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEarly-stage lung cancer represents a key focus of numerous multicenter clinical trials, but common exclusion criteria such as a prior cancer diagnosis may limit enrollment. We examined the prevalence and prognostic impact of a prior cancer diagnosis among patients with early-stage lung cancer.
methodsWe identified patients>65 years of age with early-stage lung cancer diagnosed 1996-2009 in the Surveillance, Epidemiology, and End Results-Medicare linked database. Prior cancers were characterized by type, stage, and timing with respect to the lung cancer diagnosis. All-cause and lung cancer specific-survival rates were compared between patients with and without prior cancer using Cox regression analyses and propensity scores.
resultsAmong 42,910 patients with early-stage lung cancer, one-fifth (21%) had a prior cancer. The most common prior cancers were prostate (21%), breast (18%), gastrointestinal (17%), and other genitourinary (15%). Most prior cancers were localized, and 61% were diagnosed within 5 years of the lung cancer diagnosis. There was no difference in all-cause survival between patients with and without prior cancer (hazard ratio [HR] 1.01; P=0.52). Lung cancer specific survival was improved among patients with prior cancer (HR 0.79; P<0.001).
conclusionsA prior cancer history may exclude a substantial proportion of patients with early-stage lung cancer from enrollment in clinical trials. Without adverse effect on clinical outcomes, inclusion of patients age >65 years with prior cancer in clinical trials should be considered to improve study accrual, completion rates, and generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.